Actual Body Weight for Determining Doses of Chemotherapy in Obese Cancer Patients: Evaluation of Treatment Tolerability

Medical Oncology

Volumn 20, Issue 4, 2003, Pages 363-367

  Abdah Bortnyak, Roksolyana ^a   Tsalic, Medy ^a   Haim, Nissim ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Cancer; Chemotherapy; Dose calculation; Obesity

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE;

ADULT; AGED; ALOPECIA; ARTICLE; BLADDER CANCER; BLEEDING; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; DOSE CALCULATION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GYNECOLOGIC CANCER; HUMAN; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SARCOMA; SOLID TUMOR; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OBESITY; PROSPECTIVE STUDIES;

EID: 0347994035     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:20:4:363     Document Type: Article

References (14)

1. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996;14:2590-2611.
2. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863-871.
3. Powis G, Reece P, Ahmann DL, et al. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 1987;20:219-222.
4. Lind M, Margison JM, Cerny T, et al. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug administration. Cancer Chemother Pharmacol 1989;25:139-142.
5. Rodvold KA, Rushing DA, Tewksbury DA. Doxodubicin clearance in obese. J Clin Oncol 1988;6:1321-1327.
6. Georgiadis MS, Steinberg SM, Hankins LA, et al. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst 1995;87:361-366.
7. Rosner GL, Hargis JB, Hollis DR, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: Results from Cancer and Leukemia Group B Study 8541. J Clin Oncol 1996;14:3000-3008.
8. Fleming RA, Eldridge RM, Johnson CE, et al. Disposition of high-dose methotrexate in an obese cancer patient. Cancer 1991;68:1247-1250.
9. Williamson DF. Descriptive epidemiology of body weight and body weight change in US adults. Ann Intern Med 1993;119:646-649.
10. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
11. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
12. Common Toxicity Criteria. In: Investigator's Handbook. A manual for participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment, National Cancer Institute, NIH Publication 1993;92-2740.
13. Ozer H, Armitage JO, Bennett CL, et al, for the American Society of Clinical Oncology Growth Factors Expert Panel. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 2000;18:3558-3585.
14. Gelman RS, Tormey DC, Betensky R, et al. Actual versus ideal weight in the calculation of surface area: effects on dose of 11 chemotherapy agents. Cancer Treat Rep 1987;71:907-911.